TG Therapeutics (TGTX) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

TG Therapeutics (TGTX) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

TG Therapeutics

· TGTX

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

8.601 B

-0.73%

General

Market Cap: $8.6B
Enterprise Value: $8.81B
Shares Outstanding: —
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 82.36%
Operating Margin: 17.05%
Net Profit Margin: 55.22%
FCF Margin: -0.07%
ROA: 26.93%
ROE: 72.30%
ROIC: 9.93%
Current Ratio: 4.27
Debt-to-Equity: 1.25
Revenue Per Employee: —

Valuation (TTM)

P/E: 17.91
PEG: —
P/S: 10.68
P/FCF: —
P/B: 14.14
EV/EBITDA: 65.67

Growth

Rev 1Y: 87.32%
Rev 1Y Fwd Est: 55.76%
Rev 3Y (CAGR): 504.86%
Rev 5Y (CAGR): 426.73%

Income Statement (TTM)

Revenue: $799.54M
Gross Margin: 82.36%
Operating Expenses: $522.21M
Operating Income: $136.33M
Net Profit: $441.49M

Balance Sheet

Rev 10Y (CAGR)

129.45%

EPS 1Y

1746.67%

EPS 1Y Fwd Est

-64.86%

EPS 3Y (CAGR)

—

EPS 5Y (CAGR)

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $482.58M
Working Capital: $877.19M
Total Assets: $1.64B
Net Debt: $271.87M
Total Liabilities: $1.04B
Total Equity: $604.08M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$18K
Cash Flow from Investing: $12.03M
Cash Flow from Financing: $704.56M
Free Cash Flow: -$560K
Capital Expenditures: $542K